BioMarin Pharmaceutical Inc.

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

15 八月 2019 09:45:01 条件 NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

14 八月 2019 09:45:02 条件 NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

13 八月 2019 09:45:00 条件 NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

12 八月 2019 11:44:24 条件 NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

06 八月 2019 10:30:54 条件 NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

05 八月 2019 10:11:20 条件 NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

02 八月 2019 09:45:02 条件 NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

31 七月 2019 15:08:40 条件 NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

30 七月 2019 09:47:08 条件 NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

17 十月 2018 10:48:59 条件 NetDania Notify

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

12 十二月 2016 08:29:22 条件 Nasdaq GlobeNewswire

BioMarin to Attend Three Upcoming Investor Conferences

03 十一月 2016 08:30:46 条件 Nasdaq GlobeNewswire

BioMarin Announces Third Quarter 2016 Financial Results

27 十月 2016 16:03:46 条件 Nasdaq GlobeNewswire

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

19 十月 2016 17:01:21 条件 Nasdaq GlobeNewswire

UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A

13 十月 2016 16:01:29 条件 Nasdaq GlobeNewswire

BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET

11 十月 2016 08:31:09 条件 Nasdaq GlobeNewswire

BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics

21 九月 2016 08:54:15 条件 Nasdaq GlobeNewswire

BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

15 九月 2016 08:38:09 条件 Nasdaq GlobeNewswire

BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting

08 九月 2016 04:30:29 条件 Nasdaq GlobeNewswire

BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease

06 九月 2016 16:06:27 条件 Nasdaq GlobeNewswire